Finoriq

Finoriq research workspace

Zoetis Inc. (ZTS) SEC Filings & Filing Highlights

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of. Review ZTS SEC filings, filing highlights, and disclosure activity on Finoriq.

Company Snapshot

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Company
Zoetis Inc. (ZTS)
Ticker
ZTS
Market Cap
$31.9B
Latest Price
$76.12
Industry
Biotech & Pharma

Open insider transactions

Zoetis Inc. (ZTS) Recent SEC Filing Highlights

Recent SEC filings, filing events, and disclosure highlights indexed for Zoetis Inc. (ZTS).

EventFormDate
The shareholders of the Company voted on the following proposals at the Annual MeetingAs discussed under Item 5.02 of this Current Report on Form 8-K, on May 20, 2026, the Company held the Annual Meeting. At the Annual Meetin...8-K5.072026-05-22
Effective May 20, 2026, Ms. Louise M. Parent retired from the Board of Directors of Zoetis Inc....Effective May 20, 2026, Ms. Louise M. Parent retired from the Board of Directors of Zoetis Inc. (the “Company”), prior to the Company’s 202...8-K5.022026-05-22
Zoetis Declares Third Quarter 2026 DividendZoetis Declares Third Quarter 2026 Dividend8-K7.012026-05-20
Zoetis Announces First Quarter 2026 ResultsZoetis Announces First Quarter 2026 Results8-K2.022026-05-07
Zoetis Reports Fourth Quarter and Full Year 2025 ResultsZoetis Reports Fourth Quarter and Full Year 2025 Results8-K2.022026-02-12

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.